Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2020

Conditions
Anal Canal Carcinoma
Interventions
DRUG

Docetaxel, Cisplatin and 5-Fluorouracil

Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.

Trial Locations (16)

21000

FNLCC center Georges François Leclerc, Dijon

25000

University hospital of Besançon, Besançon

25200

Hospital of Belfort-Montbeliard, Montbéliard

59000

Oscar Lambret center, Lille

75571

Saint-Antoine Hospital, Paris

69 008

Jean Mermoz Private Hospital, Lyon

34 298

Regional Institute of Cancer, Montpellier

54 519

Institute of Cancerology of Lorraine, Nancy

06 189

Antoine Lacassagne Center, Nice

75 014

Paris Saint-Joseph Hospital Group, Paris

75 248

Curie Institute, Paris

75 651

Pitié Salpétrière Hospital, Paris

75 674

Mutualist Montsouris Institute, Paris

75 908

European Georges Pompidou Hospital, Paris

51 092

University Robert Debré Hospital, Reims

67 065

Paul Strauss Center, Strasbourg

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT02402842 - Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma | Biotech Hunter | Biotech Hunter